BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chahine EB, Kelley D, Childs-Kean LM. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. Ann Pharmacother. 2018;52:352-363. [PMID: 29115151 DOI: 10.1177/1060028017741508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Cory TJ, Mu Y, Gong Y, Kodidela S, Kumar S. Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection. Expert Opin Pharmacother 2018;19:749-57. [PMID: 29634360 DOI: 10.1080/14656566.2018.1459567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Gao LH, Nie QH, Zhao XT. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. Int J Gen Med 2021;14:289-301. [PMID: 33536776 DOI: 10.2147/IJGM.S283910] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 2020;13:773-83. [PMID: 31870632 DOI: 10.1016/j.jiph.2019.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
4 Ahmed M. Era of direct acting anti-viral agents for the treatment of hepatitis C. World J Hepatol 2018; 10(10): 670-684 [PMID: 30386460 DOI: 10.4254/wjh.v10.i10.670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
5 You Y, Kim HS, Park JW, Keum G, Jang SK, Kim BM. Sulfur( vi ) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure–activity relationship studies. RSC Adv 2018;8:31803-21. [DOI: 10.1039/c8ra05471a] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 14(3): 525-534 [DOI: 10.4254/wjh.v14.i3.525] [Reference Citation Analysis]
7 Omar AM, Elfaky MA, Arold ST, Soror SH, Khayat MT, Asfour HZ, Bamane FH, El-Araby ME. 1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease. Biomolecules 2020;10:E479. [PMID: 32245218 DOI: 10.3390/biom10030479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ing Lorenzini K, Girardin F. Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients. Liver Int 2019;40:32-44. [DOI: 10.1111/liv.14283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
9 Luo A, Xu P, Wang J, Li Z, Wang S, Jiang X, Ren H, Luo Q. Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis. Medicine (Baltimore) 2019;98:e15626. [PMID: 31096473 DOI: 10.1097/MD.0000000000015626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]